Sat, Aug 23, 2014, 11:38 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Inovio Pharmaceuticals, Inc. Message Board

  • stock.dick stock.dick Aug 9, 2013 1:57 PM Flag

    Who Do You Believe, Boiler Room Pumpers and a Moonie or The 30 Year Record of Failure?

     

    Over 30 years and still NOTHING in Phase 3.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • These protein antigens trick the immune system into producing a response that will protect against a disease associated with that antigen, or eradicate infected cells or cancer cells.

      TLSR: Inovio stock has moved upward dramatically in the last six months. It is getting a lot of respect these days, isn't it?

      PC: When I first started writing about Inovio, it was so new that people were skeptical and were complaining that the company wasn't making regular gains. In early September the company signed an agreement with Roche Holding AG (RHHBY:OTCQX) for two programs, both of which are preclinical and both of which are therapeutic vaccines, INO-5150 for prostate cancer and INO-1800 for hepatitis B virus. Its stock price is doing significantly better. Moreover, it now has the resources to pursue other applications of DNA vaccines.

      TLSR: What about this impressive move upward? Is it hard to sell this as an investment idea with the stock up 260% since May?

      PC: I'm not at all bothered about the fact that price has gone up. Inovio still has extraordinary potential, and I'll tell you why. Here's one example: Monoclonal antibodies are expensive therapies, and they are difficult to handle, but this technology can actually produce monoclonal antibodies in these little inoculation sites. It puts this code in your body, and you make the antibodies yourself.

      "The ability of younger people to support older people, who are living longer, is gone. Instead of resisting that trend, we need to embrace it."
      The company has a majority-owned subsidiary, VGX Animal Health, that is using Inovio's technology on animals in Australia. The vaccine technology is causing animals to express growth hormone-releasing hormone (GHRH), which makes them larger and more fertile. Think about that. The baby boom is aging. We see athletes taking growth hormones, but because it's exogenous, coming from outside the body, it causes all kinds of problems. We know that it's possible to get effective rejuvenation of many human systems—better skin, better muscle tone, that sort of thing—with GHRH. I think that down the road, after Inovio's cancer and virus vaccines have begun to pay off and when the company is able to go where it wants to go, we're going to be looking at monoclonal antibodies, then life-extension technologies, and then other exciting applications.

      TLSR: Today Inovio has a market cap of $413 million, still small enough to be an easy acquisition. Do you anticipate this company is going to be acquired before it has a chance to grow into a fully integrated biopharma?

      PC: It's a possibility, but I don't think Inovio is going to give up all of its technology to a single company. I don't think it's necessary. The company has many partnerships. For instance, it has made extraordinary progress on malaria, and the Bill & Melinda Gates Foundation, through its PATH Malaria Vaccine Initiative (MVI), is funding preclinical development of Inovio's SynCon synthetic malaria vaccine.

      I'm hoping that the company is not acquired. I suppose shortsighted investors would be happy about it, but I really want to see Inovio CEO Joseph Kim and Dave Weiner continue to push this technology into the future.

    • Not the boiler rooms!

    • 34 years of NOTHING but dilution

    • "Do others feel that a lack of anything resembling an argument from these bashers makes them look incredibly stupid. If I came on this board and said, "Inovio is the greatest company in the world, the stock is going to a million dollars a share." Would that mean anything to you? No, there is nothing fundamental about the company mentioned in there. Nothing about its technology nothing. So why would you believe the opposite type of useless argument presented by bashers, "Inovio is going bankrupt, next stop $.20 per share". The funniest part is that some of them attempt to bash the technology like that loser slumdawg2011. Yet when they do that it is so easy to invalidate their attempt to bash something specific about the technology with verifiable facts. Anybody starting to see the pattern here?

    • In the opening section of the report, McKinsey states "….we believe these technologies will have large and disruptive impact. More importantly, the results of our research show that business leaders and policy makers-and society at large-will confront change on many fronts: in the way businesses organize themselves, how jobs are defined, how we use technology to interact with the world (and with each other), and, in the case of next-generation genomics, how we understand and manipulate living things. There will be disruptions to established norms, and there will be broad societal challenges. Nevertheless, we see considerable reason for optimism. Many technologies on the horizon offer immense opportunities. We believe that leaders can seize the opportunities, if they start preparing now."
      The McKinsey article also states: "The science of genomics is at the beginning of a new era of innovation. The rapidly declining cost of gene sequencing is making huge amounts of genetic data available, and the full power of information technology is being applied to vastly speed up the process of analyzing these data to discover how genes determine traits or mutate to cause disease. Armed with this information, scientists and companies are developing new techniques to directly write DNA and insert it into cells, building custom organisms and developing new drugs to treat cancer and other diseases. Over the coming decade, next-generation genomics technology could power rapid acceleration in the field of biology and further alter healthcare…."
      The criteria McKinsey used for identifying disruptive technology were:
      1. The technology is rapidly advancing or experiencing breakthroughs
      2. The potential scope of impact is broad
      3. Significant economic value could be affected
      4. Economic impact is potentially disruptive
      The McKinsey report defined Next-generation genomics as: "Next-generation genomics marries advances in the science of sequencing and modifying genetic material

    • How do you refute a 30 year record?

    • Hmmmmmmmmmmm

    • That is the question.

    • In the opening section of the report, McKinsey states "….we believe these technologies will have large and disruptive impact. More importantly, the results of our research show that business leaders and policy makers-and society at large-will confront change on many fronts: in the way businesses organize themselves, how jobs are defined, how we use technology to interact with the world (and with each other), and, in the case of next-generation genomics, how we understand and manipulate living things. There will be disruptions to established norms, and there will be broad societal challenges. Nevertheless, we see considerable reason for optimism. Many technologies on the horizon offer immense opportunities. We believe that leaders can seize the opportunities, if they start preparing now."
      The McKinsey article also states: "The science of genomics is at the beginning of a new era of innovation. The rapidly declining cost of gene sequencing is making huge amounts of genetic data available, and the full power of information technology is being applied to vastly speed up the process of analyzing these data to discover how genes determine traits or mutate to cause disease. Armed with this information, scientists and companies are developing new techniques to directly write DNA and insert it into cells, building custom organisms and developing new drugs to treat cancer and other diseases. Over the coming decade, next-generation genomics technology could power rapid acceleration in the field of biology and further alter healthcare…."
      The criteria McKinsey used for identifying disruptive technology were:
      1. The technology is rapidly advancing or experiencing breakthroughs
      2. The potential scope of impact is broad
      3. Significant economic value could be affected
      4. Economic impact is potentially disruptive
      The McKinsey report defined Next-generation genomics as: "Next-generation genomics marries advances in the science of sequencing and modifying genetic material with the

    • The record of FAILURE.

    • View More Messages
 
INO
10.71+0.13(+1.23%)Aug 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.